<DOC>
	<DOCNO>NCT02655549</DOCNO>
	<brief_summary>The trial investigate Px563L RPA563 , two formulation novel anthrax vaccine .</brief_summary>
	<brief_title>A Study Anthrax Vaccines Px563L RPA563 Healthy Adult Subjects</brief_title>
	<detailed_description>This Phase 1 , double-blind , randomize , placebo-controlled study evaluate safety , tolerability , immunogenicity Px563L RPA563 administer intramuscularly . All subject follow safety tolerability 393 day initial vaccination . Immunogenicity analyse perform 182 day , include interim analysis base Day 70 result , initial vaccination .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<criteria>Willing able read understand consent process sign inform consent form ( ICF ) . Females male age 18 55 , inclusive , time informed consent . Healthy stable medical condition require continuous medication . Female subject pregnant breastfeeding . A history anthrax disease receipt anthrax vaccine time past , exposure infection B. anthracis , receive investigational anthrax vaccine treatment ( e.g. , monoclonal antibody , anthrax immune globulin ) . Positive test human immunodeficiency virus ( HIV ) , hepatitis C hepatitis B ( surface antigen ) . History malignant neoplasm receipt antineoplastic agent within last 5 year , exception adequately treat , localize situ nonmelanoma skin ( e.g. , basal cell carcinoma ) cervix . History immunodeficiency , chronic illness require continuous frequent medical intervention , autoimmune disease , bleed disorder , hemoglobinopathy , prior solid organ bone marrow transplant , know history past 5 year cardiac disease . Evidence alcohol abuse ( i.e. , require treatment ) substance abuse ( i.e. , use illicit drug ) within 6 month prior screen . History severe allergy ( e.g. , anaphylaxis ) latex rubber . Subjects significant scarring , tattoo , abrasion , rash , skin abnormality plan vaccination site could interfere evaluation injection site.. Use systemic steroid immunosuppressive agent within 2 year prior screen ; use topical , intranasal , inhaled corticosteroid â‰¥10 consecutive day within 1 year prior screen . Administration license vaccine within 30 day prior screen . History anaphylaxis serious adverse reaction vaccine . Donation loss &gt; 500 mL blood donation plasma within 2 month screen , recipient blood blood product within 2 month screen . Present former member US military reservist may receive licensed anthrax vaccine , serve military arena January 1990 present time . May risk exposure anthrax may require receive licensed anthrax vaccine ( e.g. , postal worker ) . Has previously participate anthrax vaccine antiprotective antigen ( PA ) monoclonal antibody clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>